Opendata, web and dolomites

HEPCAN SIGNED

A Humanized Monoclonal Anti-Claudin1 Antibody (anti-CLDN1 mAb) for Treatment of Hepatocellular Carcinoma (HCC)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HEPCAN project word cloud

Explore the words cloud of the HEPCAN project. It provides you a very rough idea of what is the project "HEPCAN" about.

viruses    drugs    primary    carcinoma    amongst    molecules    stages    disease    continual    leads    fibrosis    therapy    progression    inappropriate    symptoms    resistance    suggesting    therapeutic    deaths    tumor    populations    damaging    alcoholic    worldwide    valuable    combination    cancer    medical    375    drug    approved    patients    77    livers    sub    closely    systemic    cells    2040    hcc    rising    compound    prognosis    population    resection    80    causes    liver    absence    fibrotic    nature    fda    aggressive    screening    monotherapy    accelerate    medicine    reaching    steatohepatitis    validate    2018    keep    mortality    owing    option    prolonging    triggers    recommended    sorafenib    amounted    heterogeneity    usually    survival    recurrence    frequent    trigger    hepatocellular    constrains    cell    fact    alcoholism    months    resistant    urgent    curative    iarc    consequently    hepatitis    unmet    diagnosis    cirrhotic    efficacy    poor    first    benefit    fatty    persistent    experiencing    precision    treatment   

Project "HEPCAN" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 150˙000.00

Map

 Project objective

Hepatocellular carcinoma is the most frequent primary liver cancer and owing to its very aggressive nature is amongst the leading cause of cancer mortality worldwide (IARC). The number of liver cancer-related deaths in Europe in 2018 amounted to 77 375, and this number is expected to keep rising, reaching an estimated number of more than 100 000 deaths in 2040 (IARC). Major causes include the hepatitis B and C viruses, alcoholism, Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. All of these medical conditions trigger liver fibrosis by damaging the liver and are closely associated with the development of HCC. As a matter of fact, more than 80% of HCC develop in fibrotic or cirrhotic livers. Early stages of liver cancer do not usually produce symptoms, and many challenges are associated with the screening of HCC, leading to its late diagnosis. The absence of effective drug treatment for HCC makes its resection the first curative option with most of the patients experiencing HCC recurrence within 5 years. All these factors contribute to the poor prognosis of the HCC patients. Sorafenib is the only currently approved systemic therapy for advanced HCC in the EU, only prolonging survival by an average of 3 months, the treatment often leads to drug resistance. Indeed, intra-tumor heterogeneity strongly constrains the therapeutic benefit of precision medicine and triggers drug-resistant sub-population of cells. Consequently, persistent treatment of drug-resistant tumor cells may accelerate tumor progression, suggesting that inappropriate and continual use of a compound on drug-resistant cancer cells is not recommended. Thus, there is an urgent unmet medical need to identify and to validate the therapeutic efficacy of new valuable molecules – i.e. targeting the existing drug-resistant cell populations -that could be used in monotherapy or in combination therapy with FDA-approved drugs to improve HCC treatment responses.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEPCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEPCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

LO-KMOF (2019)

Vapour-deposited metal-organic frameworks as high-performance gap-filling dielectrics for nanoelectronics

Read More  

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More  

TRUST (2018)

Truth and Semantics

Read More